Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SAS9: MIS Hits Primetime

Executive Summary

The Ninth Annual Symposium for the International Society for the Advance of Spine Surgery (SAS9), held this spring in London, welcomed almost 1,700 attendees, double that of 2008, and most sessions provided a spirit of optimism despite the harsh economic environment. Minimally invasive surgery (MIS) took center stage as applications widen and techniques improve, while facet joint replacement devices and materials to simplify revisions also drew crowds.

You may also be interested in...



Spine Market: A Perfect Storm

While most Wall Street analysts predict that the current economic crisis will have little effect on the spine industry over the long haul, there are storm clouds on the horizon that should put spine product manufacturers on guard. With crackdowns by the Department of Justice tipping over into the spine arena and whistleblower lawsuits regarding surgeon/industry relationships in the news, along with several important bills before Congress designed to change how the business of spine surgery is done, current financial constraints may be only the tip of the iceberg in terms of things to come.

Archus: Using Old Principles to Open a New Market in Spine

By focusing on an overlooked but critical element of spinal anatomy, the facet joint, Archus is applying established principles of total joint replacement to create a new opportunity in spine, while also expanding the potential opportunities in disc replacement.

More Heartmate Troubles For Abbott. Latest Recall Includes 14 Deaths

Abbott initiated a recall in February of thousands of Heartmate devices due to a system obstruction that can result in serious health outcomes, including death. The FDA has now designated the recall as class I.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel